FDA Clearance Tracker · P170019-S060
FoundationOne CDx (F1CDx)
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 27, 2026
Approved
Time to decision
614 days
Received Sep 20, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P170019-S060
- Device name
- FoundationOne CDx (F1CDx)
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Sep 20, 2024
- Decided
- May 27, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P170019
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval order to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic (CDx) indication for the detection of HRR gene alterations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) in patients with metastatic castrate-resistant prostate cancer (mCRPC) who may benefit from treatment with TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide).
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne Liquid CDxPMA supplement
P190032-S029 · Decided May 27, 2026 · 490 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.